Lyra Therapeutics Inc (LYRA): Price-to-Revenue Ratio

Symbol and logo of brand Lyra Therapeutics Inc (LYRA)

Lyra Therapeutics, Inc. (LYRA) develops drug delivery systems for ENT organs, though it is currently struggling with a capital shortage following failed tests. The company's rolling P/S ratio helps assess market demand, while 1.40 determines the current status of this parameter. Growth prospects rely on the success of the LYR-210 drug and its potential FDA approval for expansion into the sinus treatment market.

LYRA lyratherapeutics.com Price-to-Revenue Ratio (07/04/2022 - 03/28/2026)

Lyra Therapeutics, Inc. (LYRA) - metric breakdowns and financial figures

- share price and consensus valuation forecast:
Summary company analytics:Lyra Therapeutics
Signature product of Lyra Therapeutics Inc

For the biotech startup Lyra Therapeutics, Inc. (LYRA), the P/S ratio serves as an indicator of market expectations regarding future revenue streams. This metric is calculated as the ratio of current market capitalization to total annual sales. Analyzing the history of P/S values allows for the identification of asset overvaluation in the absence of a commercial product. In the context of failed clinical trials and restructuring, this indicator highlights the speculative nature of the share price amid scaled-back operations.

Competing companies

HLN (Haleon) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Kenvue Inc KVUE|Verona Pharma Corp - Price-to-Revenue Ratio|MENS: Market Cap to Revenue|Price-to-Revenue Coefficient Ligand Pharmaceuticals LGND|Amneal Pharmaceuticals Inc (AMRX) - Price-to-Revenue Ratio|Perrigo Company PLC - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio alvotech.com|P/S Multiple Liquidia Technologies|Price-to-Revenue Ratio Galapagos Genomics (GLPG)|ANIP: Price-to-Sales Ratio|P/S Multiple MNKD (MannKind Corp)|Price-to-Revenue Coefficient Amphastar (AMPH)|PCRX: Market Cap to Revenue|SPRY - P/S Multiple|Theravance Biopharma, Inc. (TBPH) - Price-to-Revenue Ratio|AQST (Aquestive Therapeutics) - Price-to-Revenue Ratio|SCPH (scpharmaceuticals.com) - P/S Multiple|TECX: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Tonix Pharmaceuticals Inc. (TNXP)|SXTC (SXT Pharmaceuticals) - Market Capitalization-to-Revenue Ratio|P/S Multiple EPRX (Eupraxia Pharmaceuticals)|Market Capitalization-to-Revenue Ratio BHST|Invizyne Technologies - P/S Multiple|oramed.com (ORMP) - Market Cap to Revenue|ENTX (enterabio.com) - Market Cap to Revenue|Market Cap to Revenue Ratio HYFT|ABVC (ABVC BioPharma, Inc) - P/S Multiple|P/S Multiple cumberlandpharma.com|Price-to-Revenue Ratio Quantum BioPharma (QNTM)|FibroGen (FGEN) - Price-to-Revenue Multiple|P/S Multiple TELO (telomirpharma.com)|RANI - Market Cap to Revenue|SNYR - Price-to-Revenue Ratio|rallybio.com - Market Cap to Sales Volume|LEXX: P/S Multiple|Market Cap to Revenue Pulmatrix Inc|PTHL (Pheton Holdings) - P/S Multiple|Price to Sales Aptorum Group Limited APM|P/S Multiple IBO|Market Cap to Sales Volume TNFA|cbdMD, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio PRFX|Altamira Therapeutics Ltd. - P/S Multiple|LIPO: Price-to-Revenue Ratio|OPTN: P/S Multiple|Price-to-Sales Ratio PIRS (Pieris Pharmaceuticals)|PROC (Procaps) - P/S Multiple|PTPI (Petros Pharmaceuticals Inc) - Market Cap to Sales Volume|P/S Multiple QLI|SLRN - Price to Sales|P/S Multiple TFFP (TFF Pharmaceuticals, Inc)